Study Shows Superior Efficacy For TAXUS(R) Express(R) Stents Compared To Bare-Metal Stents In Heart Attack Patients At Two Years

Boston Scientific Corporation (NYSE: BSX) announced two-year follow-up data from the HORIZONS-AMI trial.